ABBVIE

Everest Medicines unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day, showcasing a fully integrated system spanning antigen design to manufacturing.

Oxford BioTherapeutics announced that Boehringer Ingelheim has selected a third drug candidate targeting OB33 to advance into IND-enabling studies under their ongoing collaboration.

Neurocrine Biosciences has launched a Phase 1 first-in-human clinical study evaluating NBIP-01435, a long-acting corticotropin-releasing factor type 1 receptor antagonist for congenital adrenal hyperplasia treatment.

AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1 billion to gain access to CPTX2309, a potential first-in-class treatment for autoimmune diseases currently in Phase 1 trials.

AbbVie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion in cash, gaining access to innovative in vivo CAR-T technology.

Allergan Aesthetics has received FDA acceptance for review of its supplemental premarket approval application to expand SKINVIVE by Juvéderm's indication from cheek smoothness to include neck line treatment.

Total M&A deal value in Alzheimer's disease jumped from $2 billion in 2022 to $18 billion in 2024, representing a 780% increase following the approval of disease-modifying treatments.

Prokaryotics Inc. has entered into a licensing agreement with Northern Antibiotics for worldwide rights to develop NAB741, a non-bioactive polymyxin designed to enhance antibiotic efficacy against Gram-negative bacteria.

Licensing agreements for CNS-targeted oligonucleotide therapeutics increased 339% from 2023 to 2024, reaching $2.81 billion in total deal value according to GlobalData's analysis.

Simcere Zaiming has dosed the first US patient in a Phase 1 trial of SIM0500, a trispecific antibody targeting GPRC5D, BCMA, and CD3 for relapsed/refractory multiple myeloma treatment.